©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
Chimeric Substitutions of the Actin-binding Loop Activate Dephosphorylated but Not Phosphorylated Smooth Muscle Heavy Meromyosin (*)

(Received for publication, September 25, 1995; and in revised form, October 23, 1995)

Arthur S. Rovner (1) Yelena Freyzon (2) Kathleen M. Trybus (2)(§)

From the  (1)Department of Molecular Physiology and Biophysics, University of Vermont, Burlington, Vermont 05405 and (2)Rosenstiel Basic Medical Sciences Research Center, Brandeis University, Waltham, Massachusetts 02254-9110

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
REFERENCES

ABSTRACT

Regulatory light chain (RLC) phosphorylation is necessary to activate smooth muscle myosin, unlike constitutively active striated muscle myosins. Here we show that an actin-binding surface loop located at the 50/20-kDa junction contributes to this fundamental difference between myosins. Substitution of the native actin-binding loop of smooth muscle heavy meromyosin (HMM) with that from either skeletal or beta-cardiac myosin caused the chimeric HMMs to become unregulated like the myosin from which the loop was derived. Dephosphorylated chimeric HMMs gained the ability to move actin in a motility assay and had 50-70% of the actin-activated ATPase activity of phosphorylated wild-type HMM. Direct binding measurements showed that the affinity of HMM for actin in the presence of MgATP was unaffected by loop substitution; thus the rate of a step other than binding is increased. Phosphorylation of the chimeras did not lead to a higher V(max) than obtained for wild-type HMM. In the absence of actin, a foreign loop did not affect nucleotide trapping. Native regulated molecules have thus evolved a loop sequence which prevents rapid product release by actin when the RLC is dephosphorylated, thereby allowing activity to be controlled by RLC phosphorylation.


INTRODUCTION

Myosins differ from each other in how fast they can move actin, the rates of their actin-activated ATPases, and whether or not these activities are regulated. It has been recently suggested that a divergent surface loop at the actin-binding interface ``tunes'' the rate of phosphate release and thus sets the maximum velocity (V(max)) for ATPase activity. A second loop, at the 25/50-kDa interface near the ATP-binding site, was proposed to control the rate of ADP release and thus be responsible for determining the velocity at which different myosins move actin (Spudich, 1994). The actin-activated ATPase activity of a chimeric Dictyostelium myosin containing the actin-binding loop from skeletal muscle myosin was 5-fold higher than wild-type Dictyostelium myosin, providing experimental evidence in support of the first part of this hypothesis (Uyeda et al., 1994). This study did not show if such a generalization would hold true for other myosin motors nor was the question of heavy chain sequences involved in regulation of activity addressed.

The molecular step that is controlled by light chain phosphorylation in smooth muscle myosin is phosphate release from the active site (Sellers, 1985). It has been recently proposed that myosin is a ``back door'' enzyme, whereby the cleaved phosphate leaves via a cleft in the 50-kDa domain, instead of through the nucleotide-binding pocket from which it entered. Binding of actin is suggested to promote movement of the highly conserved P-loop near the active site so that phosphate can leave (Yount et al., 1995). The interaction of actin with myosin probably involves several steps; the first is thought to be a weak interaction between the N terminus of actin and the 50/20-kDa junction of myosin, followed by stronger interactions involving hydrophobic residues in the upper and lower 50-kDa domains (Rayment et al., 1993b; Holmes, 1995). Mutation of regions involved in actin binding might therefore be expected to affect regulation of ATPase activity. Here we show that smooth muscle HMM (^1)can be turned into an unregulated, constitutively active molecule simply by replacing its native actin-binding loop (ABL) at the 50/20-kDa junction with that from an unregulated striated muscle myosin.


MATERIALS AND METHODS

Construction of Chimeric Actin-binding Loop HC cDNAs

The polymerase chain reaction (PCR) was used to construct chimeric smooth muscle myosin heavy chain (HC) DNA molecules containing the 50/20-kDa actin-binding loop from chicken skeletal muscle (amino acid sequence GGEAEGGGGKKGGKKK) (Maita et al., 1987) or rat beta-cardiac myosin (ANYAGADAPVDKGKGKAKK) (McNally et al., 1989). The sequence (residues 626-653) of the native smooth muscle myosin loop is KDVDRIVGLDQMAKMTESSLPSASKTKK (Yanagisawa et al., 1987). For each construct, two overlapping PCR products were cleaved internally at a unique common restriction site and ligated. The resulting approx350-base pair chimeric PCR products were cleaved at unique BstEII (nucleotides 1,767-1,773) and AflII (nucleotides 2,019-2,024) sites and ligated as a cassette into an equivalently cleaved chicken gizzard HC cDNA. DNA sequencing verified the fidelity of the inserted PCR sequence.

Infection of Sf9 Cells and Biochemical Methods

Recombinant baculovirus was isolated by conventional protocols (O'Reilly et al., 1992). Sf9 cells in suspension culture were coinfected with viral particles containing the HMM HC construct (intermediate HMM, 1175-amino acid HC) and a virus expressing both the smooth muscle regulatory (RLC) (Trybus and Chatman, 1993) and essential light chains (Nabeshima et al., 1987). Purification and phosphorylation of the expressed HMM were as described (Trybus, 1994). Immunoblots of glycerol gels were used to verify RLC phosphorylation (Perrie and Perry, 1970).

ATPase and Binding Assays

The concentration of HMM was determined from its NH(4)-ATPase activity relative to a known concentration of purified myosin prepared from turkey gizzard. The buffer for this assay was 0.4 M NH(4)Cl, 25 mM Trizma hydrochloride (pH 8.0 at room temperature), 0.2 M sucrose, 2 mM EDTA, 1 mM dithiothreitol, 4 mM NH(4)-ATP. Typically, 50-80% of the total protein was active HMM. Immunoblots confirmed that the additional bands in the preparation are not derived from the myosin HC. To establish that the WT and mutants have the same NH(4)-ATPase activity, aliquots of protein with equivalent amounts of NH(4)-ATPase activity were loaded on SDS gels and scanned by densitometry. Within experimental error, bands of equal intensity had equal NH(4)-ATPase activity. The actin-activated ATPase activity of the expressed constructs is thus based on this concentration determination.

Actin-activated Mg-ATPase activity was measured as a function of actin concentration in 10 mM imidazole hydrochloride, pH 7.0, 8 mM KCl, 1 mM MgCl(2), 1 mM EGTA, 1 mM dithiothreitol, 2 mM MgATP (37 °C, 20 µg/ml HMM). Inorganic phosphate was determined colorimetrically (White, 1982).

Binding of mutant and WT-HMMs to actin in the presence of MgATP was determined by a sedimentation assay. A longer tail-length WT-HMM construct of 1329 amino acids was used (Trybus, 1994) to allow the mutant and WT-HMMs to be distinguished in a single gel lane. SABL-HMM and long WT-HMM (0.6 µM heads) were mixed with varying concentrations of actin in the buffer used for ATPase measurements. One mM MgATP was added, and the sample was spun at 350,000 times g for 20 min. Equal volumes of the supernatant and pelleted fractions were run on 9% SDS gels, and the percent of HMM bound was determined by densitometry. Control experiments showed that in the absence of actin essentially all the protein was in the supernatant and that in the absence of MgATP all the protein bound to actin.

Single Turnover Assay

[P]ATP (0.9 µM; specific activity, 1.8 times 10^7 cpm/nmol) was added to HMM (0.46 µM myosin heads) in a buffer containing 25 mM imidazole HCl, pH 7.5, 25 mM KCl, 0.1 mM MgCl(2), 1 mM EGTA, and 1 mM dithiothreitol. A 20-fold molar excess of unlabeled ATP was added 10 s later. Nucleotide bound to HMM as a function of time was determined by rapid centrifugation through a dried gel filtration column (Trybus, 1989). NH(4)-ATPase activity was used to determine the percent recovery of HMM. Control assays were carried out in a buffer containing 0.6 M KCl, conditions where nucleotide trapping cannot occur.

In Vitro Motility Assay

Actin filament motility was measured at 30°C as described in Trybus and Chatman(1993). An anti-rod monoclonal antibody (Ab S2.2; Trybus and Henry, 1989) was used to bind the HMM to the nitrocellulose surface (Trybus, 1994). Where noted, some assays were done at 60 mM KCl, 0.7% methyl cellulose.


RESULTS

Dephosphorylated Chimeric Mutants Show High Actin-activated ATPase Activities

Two chimeric smooth muscle HMM mutants, in which the native 50/20-kDa actin-binding loop was substituted with that from skeletal muscle myosin or beta-cardiac myosin, were co-expressed with light chains in the baculovirus system. The mutants were named SABL-HMM (Skeletal Actin Binding Loop) and CABL-HMM (Cardiac Actin Binding Loop) (see ``Materials and Methods'' for sequences). SABL-HMM and CABL-HMM are indistinguishable from WT-HMM in their heavy and light chain complement (Fig. 1A).


Figure 1: A, 12% acrylamide SDS gel of turkey gizzard myosin prepared from tissue (lane 1), expressed WT-HMM (lane 2), SABL-HMM (lane 3), and CABL-HMM (lane 4). Arrowheads mark the position of the myosin HCs, the 20-kDa RLC, and the 17-kDa essential light chain (ELC). B, equal binding of SABL-HMM and long WT-HMM to actin in the presence of MgATP. Supernatant (S) and pelleted (P) fractions following sedimentation of both HMMs with 125 µM actin and 1 mM MgATP (lanes 1, 2) are shown. Controls in the absence of MgATP show that all the protein can bind to actin (lanes 3 and 4). See Fig. 2D for a plot of percent bound as a function of actin concentration. C, immunoblot of a glycerol/charge gel shows the state of phosphorylation of samples used in steady-state ATPase assays. Dephosphorylated and phosphorylated WT-HMM (lanes 1 and 2) and dephosphorylated and phosphorylated SABL-HMM (lanes 3 and 4) are shown. Arrowheads mark the position of dephosphorylated (deP) and phosphorylated (P) RLC. The band with the fastest mobility in lane 4 is RLC, which was phosphorylated at both Thr-18 and Ser-19.




Figure 2: Actin-activated ATPase activity and binding of mutant and WT-HMMs. A-C, phosphorylated HMM (filled circles) and dephosphorylated HMM (open circles) are shown. V(max) and K values, respectively, are as follows: A, 3.1±.34 s and 14 µM for dephosphorylated SABL-HMM, 2.6 ± 0.12 s and <1 µM for phosphorylated SABL-HMM; B, 2.0 ± 0.45 s and 24 µM for dephosphorylated CABL-HMM, 3.7 ± 0.68 s and 13 µM for phosphorylated CABL-HMM; C, 4.2 ± 1.1 s and 57 µM for phosphorylated WT-HMM. Measurements were made on five independent preparations of SABL-HMM, two of CABL-HMM, and seven of WT-HMM. Data were fitted using the equation, V = V(max)*[actin]/(K + [actin]). D, percent WT-HMM (open squares) and SABL-HMM (filled squares) bound to actin in the presence of MgATP as a function of actin concentration. See Fig. 1B for an example of the raw data.



The actin-activated ATPase activity of dephosphorylated and phosphorylated WT-HMM, SABL-HMM, and CABL-HMM were determined (Fig. 2, A-C). The extrapolated V(max) values obtained from the illustrated best fit curves for the phosphorylated species are: 2.6 ± 0.12 s for SABL-HMM, 3.7 ± 0.68 s for phosphorylated CABL-HMM, and 4.2 ± 1.1 s for phosphorylated WT-HMM. These ATPase activities do not reflect the higher activity of the myosin from which the loop sequence was derived.

Surprisingly, the major effect of the loop mutations was to activate the dephosphorylated species. The V(max) of dephosphorylated SABL-HMM (3.1 ± 0.34 s) was virtually identical to its phosphorylated counterpart, while dephosphorylated CABL-HMM had a V(max) of 2.0 ± 0.45 s, only 2-fold less than phosphorylated CABL-HMM. Immunoblots of the samples used for the ATPase assay showed that the levels of phosphorylation in the phosphatase-treated samples were negligible (Fig. 1C).

The dephosphorylated chimeric mutants had a 3-4-fold lower K(m) for actin than phosphorylated WT-HMM (see Fig. 2legend for values). Phosphorylation decreased the K(m) further to <1 µM for phosphorylated SABL-HMM. Thus at low actin concentrations, the apparent effect of the ABL mutations is to increase activity, but this trend does not persist when the values are extrapolated to V(max).

WT and SABL-HMM Bind to Actin with Equal Affinity

To determine if the activation of the dephosphorylated HMMs is due to an increase in binding of the chimeras to actin, a sedimentation assay was performed (Fig. 1B and Fig. 2D). The results show that the binding of dephosphorylated WT-HMM and dephosphorylated SABL-HMM to actin in the presence of MgATP was indistinguishable. The binding constant was approximately 8 times 10^3M, consistent with earlier measurements with chymotryptic HMM (Sellers et al., 1982). Activation must therefore result from changes to a kinetic step other than binding to actin.

SABL-HMM Traps Nucleotide in the Absence of Actin

To determine whether the ABL chimeras were also unregulated in the absence of actin, single-turnover assays were performed on dephosphorylated WT-HMM and SABL-HMM (Fig. 3). SABL-HMM was chosen because its actin-activated ATPase activity was completely unregulated. WT-HMM trapped nucleotide in low ionic strength buffer (25 mM KCl), releasing hydrolyzed P(i) at the rate of only 0.00032 s (tof 35 min) (data not shown). SABL-HMM released P(i) at the rate of 0.00066 s (t= 17.5 min (Fig. 3). Incubation in a high ionic strength buffer (0.6 M KCl) had the expected effect of speeding the rate of phosphate release for both constructs. These results show that dephosphorylated SABL-HMM can be ``turned off'' in the absence of actin.


Figure 3: Release of P in a single turnover from dephosphorylated SABL-HMM. Data were obtained at 25 mM KCl (filled circles) and 0.6 M KCl (open circles). Rate constants were obtained using the best fit equation of the form, y = N(0)*e, where N(0) is moles of phosphate bound per mol of HMM head at t = 0, k is the rate constant, and t is time.



Actin Movement by Chimeric Mutants Is Not Regulated by RLC Phosphorylation

Dephosphorylated SABL and CABL-HMMs both gained the ability to move actin in an in vitro motility assay (Fig. 4). The velocity of movement by SABL-HMM was independent of phosphorylation, while the velocity of phosphorylated CABL-HMM was only 1.5-fold higher than dephosphorylated CABL-HMM. Thus the degree of regulation found in the motility assays was similar to that observed in the ATPase measurements. Dephosphorylated WT-HMM showed no movement under the conditions of our assay and thus was completely regulated. One motility experiment conducted at 60 mM KCl showed that dephosphorylated SABL-HMM was still active at an ionic strength more closely approximating physiological conditions.


Figure 4: Velocity of actin movement by phosphorylated and dephosphorylated HMM. All values are mean velocities ± S.D. for three independent preparations of SABL-HMM, two of CABL-HMM, and four of WT-HMM. For each preparation, geq12 filaments were measured to obtain an average velocity for each condition. Dephosphorylated (deP) WT-HMM did not show any measurable motility.



The chimeric substitutions caused a decrease in the velocity of actin filament movement by the phosphorylated HMM species, from 1.1 µm/s with WT-HMM to 0.34 µm/s with SABL-HMM and 0.80 µm/s with CABL-HMM. The motility with SABL-HMM was about 2-fold lower than would be expected based on the ATPase measurements, which were 60-70% of phosphorylated WT-HMM.


DISCUSSION

The sequence of the ABL at the 50/20-kDa junction in the myosin head is highly divergent, suggesting that it could confer isoform-specific properties onto myosin. Here we show that the native sequence of the smooth muscle myosin ABL is required for regulation by light chain phosphorylation. Replacement of the native ABL with that from unregulated fast skeletal (SABL-HMM) or beta-cardiac myosin (CABL-HMM) caused dephosphorylated HMM, which is normally in the ``off'' state, to proceed through its ATPase cycle with at least 50% the rate of phosphorylated WT-HMM and move actin in a motility assay.

How can a loop at the opposite end of the head from the RLC affect regulation? Loss of regulation implies that inorganic phosphate can no longer be trapped at the active site in the presence of actin. The ABL straddles the cleft that separates the upper and lower 50-kDa domains (Rayment et al., 1993a) and may be instrumental in initiating a multistep process that leads to cleft closure and release of phosphate through the ``back door'' (Yount et al., 1995). Thus there is a fairly direct line of communication between the ABL and the phosphate-binding site at the base of the cleft in the 50-kDa domain, and it is reasonable that changing the way actin interacts with a given ABL could inhibit or facilitate cleft closure and hence affect regulation. Continuity between the ABL, the nucleotide-binding site, and the RLC is maintained through the 20-kDa portion of the HC, which traverses the length of the head; the ABL is adjacent to the N terminus of the 20-kDa segment, which continues past the nucleotide site, and ends in a long alpha-helix to which the LCs bind (Rayment et al., 1993a). The balance between two lines of communication, RLC active site ABL, therefore determines whether or not phosphate is released.

Spudich and colleagues (Uyeda et al., 1994) suggested that the 50/20-kDa loop affects the rate-limiting step of myosin's ATPase cycle, based on the observation that a chimeric phosphorylated Dictyostelium myosin with a fast skeletal ABL had a 5-fold higher actin-activated ATPase than WT myosin. Because the actin-activated ATPase activity of phosphorylated smooth muscle SABL or CABL-HMM was not enhanced, this role for the loop is not a general feature of all myosin motors. The ABL mutations decreased the K(m) for actin, resulting in an apparent activation at low actin concentrations, but this increase does not persist at high actin concentrations.

Activation of the dephosphorylated chimeras was not due to an increased affinity for actin in the presence of MgATP. This result implies that the foreign loops increase the rate of a transition other than binding. The molecular step is probably the same as that activated by RLC phosphorylation in the native molecule, which is phosphate release or a step just preceding release but following hydrolysis (Sellers et al., 1982). The similarity in the V(max) values for the dephosphorylated and phosphorylated chimeras argues for this interpretation.

Introduction of the ABL loop into smooth muscle HMM must also affect the rate of other kinetic transitions in the ATPase cycle. The K(m) for SABL-HMM is significantly lower than for phosphorylated WT-HMM. The leftward shift in K(m) upon phosphorylation of SABL-HMM is consistent with the observation that phosphorylation increases binding to actin (Sellers et al., 1982). Since more than one elementary rate constant contributes to K(m) in a model-dependent way (Taylor, 1979), we cannot speculate at present as to which step is altered by the introduction of chimeric ABLs. The reduced rate of motility with SABL-HMM implies that ADP release (Siemankowski et al., 1985) may also be affected by the skeletal loop sequence.

Regulation of activity in smooth muscle myosin also occurs in the absence of actin. The most striking example of this is the ``trapping'' of nucleotide at the active site when myosin adopts the folded monomeric conformation (Cross et al. 1986), but chymotryptic HMM (Sellers, 1985) and dephosphorylated myosin filaments (Trybus, 1989) also show a strong inhibition of product release. Dephosphorylated SABL-HMM retained the ability to trap products, showing that foreign loops facilitate phosphate release only in the presence of actin. The ABL is likely to be disordered and flexible since it is not seen in the crystal structure (Rayment et al., 1993a) and can be readily proteolyzed (Mornet et al., 1981). When it interacts with actin, the ABL probably adopts a more ordered structure and thereby increases its influence on the active site.

Nineteen of the 26 residues in the actin-binding loops from myosins regulated by light chain phosphorylation are identical. Only one charged residue is not conserved between smooth (Yanagisawa et al., 1987; Babij et al., 1991) and non-muscle myosin (Shohet et al., 1989), suggesting that interactions involving these residues are necessary to preserve regulation. Two features differ between the loops from regulated and unregulated myosins. 1) The net positive charge of the loop from smooth muscle myosin ABL (+2) is less than that from beta-cardiac or skeletal muscle myosin (both +3), although this charge difference did not cause an increase in binding affinity to actin, and 2) the smooth ABL is longer (26 residues) than that from either beta-cardiac (19 residues) or from skeletal muscle myosin (16 residues). CABL-HMM retained a somewhat higher degree of regulation than SABL-HMM, but it remains to be established if the length of the ABL is the critical factor in accounting for this trend.

These results suggest that one difference between regulated and unregulated myosins involves a highly divergent surface loop. The sequence of the actin-binding loop from smooth muscle myosin has been conserved so that its binding to actin does not overcome the inhibition of product release imposed by a dephosphorylated RLC. Regulation is thus an intricate mechanism of how two spatially distant sites, the RLC and the actomyosin interface, communicate with the active site.


FOOTNOTES

*
This work was supported by National Institutes of Health Grant HL38113 (to K. M. T.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
Established Investigator of the American Heart Association. To whom correspondence should be addressed. Tel.: 617-736-2448; Fax: 617-736-2405; trybus@hydra.rose.brandeis.edu.

(^1)
The abbreviations used are: HMM, heavy meromyosin; ABL, actin-binding loop at the 50/20-kDa interface of the myosin heavy chain; CABL, beta-cardiac actin-binding loop; SABL, skeletal actin-binding loop; HC, myosin heavy chain; PCR, polymerase chain reaction; RLC, regulatory light chain; WT, wild-type.


REFERENCES

  1. Babij, P., Kelly, C., and Periasamy, M. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 10676-10680 [Medline]
  2. Cross, R. A., Cross, K. E., and Sobieszek, A. (1986) EMBO J. 5, 2637-2641 [Medline]
  3. Holmes, K. C. (1995) Biophys. J. 68, (suppl.) 2-7
  4. Maita, T., Hayashida, M., Tanioka, Y., Komine, Y., and Matsuda, G. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 416-420 [Medline]
  5. McNally, E. M., Kraft, R., Bravo-Zehnder, M., Taylor, D. A., and Leinwand, L. A. (1989) J. Mol. Biol. 210, 665-671 [Medline]
  6. Mornet, D., Bertrand, R., Pantel, P., Audemard, E., and Kassab, R. (1981) Biochemistry 20, 2110-2120 [Medline]
  7. Nabeshima, Y., Nabeshima, Y., Nonomura, Y., and Fujii-Kuriyama, Y. (1987) J. Biol. Chem. 262, 10608-10612 [Medline]
  8. O'Reilly, D. R., Miller, L. K., and Luckow, V. A. (1992) Baculovirus Expression Vectors: A Laboratory Manual , W. H. Freeman, New York
  9. Perrie, W. T., and Perry, S. V. (1970) Biochem. J. 119, 31-38 [Medline]
  10. Rayment, I., Rypniewski, W. R., Schmidt-Base, K., Smith, R., Tomchick, D. R., Benning, M. M., Winkelmann, D. A., Wesenberg, G., and Holden, H. M. (1993a) Science 261, 50-58 [Medline]
  11. Rayment, I., Holden, H. M., Whittaker, M., Yohn, C. B., Lorenz, M., Holmes, K. C., and Milligan, R. A. (1993b) Science 261, 58-65 [Medline]
  12. Sellers, J. R. (1985) J. Biol. Chem. 260, 15815-15819 [Medline]
  13. Sellers, J. R., Eisenberg, E., and Adelstein, R. S. (1982) J. Biol. Chem. 257, 13880-13883 [Medline]
  14. Shohet, R. V., Conti, M. A., Kawamoto, S., Preston, Y. A., Brill, D. A., and Adelstein, R. S. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 7726-7730 [Medline]
  15. Siemankowski, R. F., Wiseman, M. O., and White, H. D. (1985) Proc. Natl. Acad. Sci. U. S. A. 82, 658-662 [Medline]
  16. Spudich, J. A. (1994) Nature 372, 515-518 [Medline]
  17. Taylor, E. W. (1979) CRC Crit. Rev. Biochem. 6, 103-164
  18. Trybus, K. M. (1989) J. Cell Biol. 109, 2887-2894 [Medline]
  19. Trybus, K. M. (1994) J. Biol. Chem. 269, 20819-20822 [Medline]
  20. Trybus, K. M., and Chatman, T. A. (1993) J. Biol. Chem. 268, 4412-4419 [Medline]
  21. Trybus, K. M., and Henry, L. (1989) J. Cell Biol. 109, 2879-2886 [Medline]
  22. Uyeda, T. Q. P., Ruppel, K. M., and Spudich, J. A. (1994) Nature 368, 567-569 [Medline]
  23. White, H. D. (1982) Methods Enzymol. 85, 698-708 [Medline]
  24. Yanagisawa, M., Hamada, Y., Katsuragawa, Y., Imamura, M., Mikawa, T., and Masaki, T. (1987) J. Mol. Biol. 198, 143-157 [Medline]
  25. Yount, R. G., Lawson, D., and Rayment, I. (1995) Biophys. J. 68, (suppl.) 44-49

©1995 by The American Society for Biochemistry and Molecular Biology, Inc.